Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
AstraZeneca PLC ADR (AZN)
The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Tangible Asset Value is very stable compared to the past year. As of the 19th of April 2024, Intangibles To Total Assets is likely to grow to 0.60, while Total Current Assets are likely to drop about 15.3 B. The entity currently falls under 'Mega-Cap' category with a total capitalization of 211.61 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AstraZeneca PLC's market, we take the total number of its shares issued and multiply it by AstraZeneca PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. AstraZeneca PLC ADR shows a prevailing Real Value of $59.91 per share. The current price of the firm is $68.36. Our model approximates the value of AstraZeneca PLC ADR from analyzing the firm fundamentals such as Profit Margin of 0.13 %, return on equity of 0.16, and Current Valuation of 130.04 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Allergan Plc (AGN)
The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a total capitalization of 63.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allergan Plc's market, we take the total number of its shares issued and multiply it by Allergan Plc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Abbott Laboratories (ABT)
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 182.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abbott Laboratories's market, we take the total number of its shares issued and multiply it by Abbott Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Abbott Laboratories shows a prevailing Real Value of $109.84 per share. The current price of the firm is $105.27. Our model approximates the value of Abbott Laboratories from analyzing the firm fundamentals such as return on equity of 0.15, and Profit Margin of 0.14 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
FibroGen (FGEN)
The company has return on total asset (ROA) of (0.3554) % which means that it has lost $0.3554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.24. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 19th of April 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95. The entity currently falls under 'Small-Cap' category with a current market capitalization of 115.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate FibroGen's market, we take the total number of its shares issued and multiply it by FibroGen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of (0.2967) % which means that it has lost $0.2967 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.48, whereas Return On Tangible Assets are forecasted to decline to (0.64). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Current Asset Value is expected to grow to about 15.6 M, whereas Total Assets are forecasted to decline to about 16.1 M. The entity currently falls under 'Small-Cap' category with a current market capitalization of 266.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fennec Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Fennec Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Fennec Pharmaceuticals shows a prevailing Real Value of $11.27 per share. The current price of the firm is $9.57. Our model computes the value of Fennec Pharmaceuticals from reviewing the firm fundamentals such as Current Valuation of 277.03 M, profit margin of (0.76) %, and Shares Outstanding of 27.1 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Fate Therapeutics (FATE)
The company has return on total asset (ROA) of (0.1832) % which means that it has lost $0.1832 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3776) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, Fate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 584.4 M, whereas Non Currrent Assets Other are forecasted to decline to 8,549. The entity currently falls under 'Small-Cap' category with a current market capitalization of 573.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fate Therapeutics's market, we take the total number of its shares issued and multiply it by Fate Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
108.71 Million
At present, Fate Therapeutics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Evolus Inc (EOLS)
The company has return on total asset (ROA) of (0.123) % which means that it has lost $0.123 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.7929) %, meaning that it created substantial loss on money invested by shareholders. Evolus' management efficiency ratios could be used to measure how well Evolus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.13 in 2024, whereas Return On Tangible Assets are likely to drop (0.54) in 2024. At this time, Evolus' Total Assets are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.57 in 2024, whereas Non Current Assets Total are likely to drop slightly above 63.4 M in 2024. The firm currently falls under 'Small-Cap' category with a current market capitalization of 710.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evolus's market, we take the total number of its shares issued and multiply it by Evolus's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Evolus Inc shows a prevailing Real Value of $13.75 per share. The current price of the firm is $11.56. Our model computes the value of Evolus Inc from reviewing the firm fundamentals such as Profit Margin of (0.31) %, shares outstanding of 61.5 M, and Current Valuation of 733.54 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
AstraZeneca PLC ADR (AZN)
The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Tangible Asset Value is very stable compared to the past year. As of the 19th of April 2024, Intangibles To Total Assets is likely to grow to 0.60, while Total Current Assets are likely to drop about 15.3 B. The entity currently falls under 'Mega-Cap' category with a total capitalization of 211.61 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AstraZeneca PLC's market, we take the total number of its shares issued and multiply it by AstraZeneca PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. AstraZeneca PLC ADR shows a prevailing Real Value of $59.91 per share. The current price of the firm is $68.36. Our model approximates the value of AstraZeneca PLC ADR from analyzing the firm fundamentals such as Profit Margin of 0.13 %, return on equity of 0.16, and Current Valuation of 130.04 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Allergan Plc (AGN)
The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a total capitalization of 63.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allergan Plc's market, we take the total number of its shares issued and multiply it by Allergan Plc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Abbott Laboratories (ABT)
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 182.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abbott Laboratories's market, we take the total number of its shares issued and multiply it by Abbott Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Abbott Laboratories shows a prevailing Real Value of $109.84 per share. The current price of the firm is $105.27. Our model approximates the value of Abbott Laboratories from analyzing the firm fundamentals such as return on equity of 0.15, and Profit Margin of 0.14 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
FibroGen (FGEN)
The company has return on total asset (ROA) of (0.3554) % which means that it has lost $0.3554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.24. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 19th of April 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95. The entity currently falls under 'Small-Cap' category with a current market capitalization of 115.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate FibroGen's market, we take the total number of its shares issued and multiply it by FibroGen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of (0.2967) % which means that it has lost $0.2967 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.48, whereas Return On Tangible Assets are forecasted to decline to (0.64). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Current Asset Value is expected to grow to about 15.6 M, whereas Total Assets are forecasted to decline to about 16.1 M. The entity currently falls under 'Small-Cap' category with a current market capitalization of 266.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fennec Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Fennec Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Fennec Pharmaceuticals shows a prevailing Real Value of $11.27 per share. The current price of the firm is $9.57. Our model computes the value of Fennec Pharmaceuticals from reviewing the firm fundamentals such as Current Valuation of 277.03 M, profit margin of (0.76) %, and Shares Outstanding of 27.1 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Fate Therapeutics (FATE)
The company has return on total asset (ROA) of (0.1832) % which means that it has lost $0.1832 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3776) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, Fate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 584.4 M, whereas Non Currrent Assets Other are forecasted to decline to 8,549. The entity currently falls under 'Small-Cap' category with a current market capitalization of 573.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fate Therapeutics's market, we take the total number of its shares issued and multiply it by Fate Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
108.71 Million
At present, Fate Therapeutics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Evolus Inc (EOLS)
The company has return on total asset (ROA) of (0.123) % which means that it has lost $0.123 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.7929) %, meaning that it created substantial loss on money invested by shareholders. Evolus' management efficiency ratios could be used to measure how well Evolus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.13 in 2024, whereas Return On Tangible Assets are likely to drop (0.54) in 2024. At this time, Evolus' Total Assets are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.57 in 2024, whereas Non Current Assets Total are likely to drop slightly above 63.4 M in 2024. The firm currently falls under 'Small-Cap' category with a current market capitalization of 710.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evolus's market, we take the total number of its shares issued and multiply it by Evolus's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Evolus Inc shows a prevailing Real Value of $13.75 per share. The current price of the firm is $11.56. Our model computes the value of Evolus Inc from reviewing the firm fundamentals such as Profit Margin of (0.31) %, shares outstanding of 61.5 M, and Current Valuation of 733.54 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Portfolio Optimization Now
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
